Cargando…

Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers

Combined loss of tumor suppressors (TSPs), PTEN, TP53, and RB1, is highly associated with small cell carcinoma of prostate phenotype. Recent genomic studies of human tumors as well as analyses in mouse genetic models have revealed a unique role for these TSPs in dictating epithelial lineage plastici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soundararajan, Rama, Aparicio, Ana M., Logothetis, Christopher J., Mani, Sendurai A., Maity, Sankar N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862804/ https://www.ncbi.nlm.nih.gov/pubmed/29600194 http://dx.doi.org/10.3389/fonc.2018.00069

Ejemplares similares

Epithelial-to-Mesenchymal Plasticity in Circulating Tumor Cell Lines Sequentially Derived from a Patient with Colorectal Cancer
por: Balcik-Ercin, Pelin, et al.
Publicado: (2021)

A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome
por: Soundararajan, Rama, et al.
Publicado: (2015)

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
por: Luo, Jie, et al.
Publicado: (2019)

Neuroendocrine and Aggressive-Variant Prostate Cancer
por: Spetsieris, Nicholas, et al.
Publicado: (2020)

Lineage Plasticity and Stemness Phenotypes in Prostate Cancer: Harnessing the Power of Integrated “Omics” Approaches to Explore Measurable Metrics
por: Logotheti, Souzana, et al.
Publicado: (2023)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
por: Maitland, Norman J.
Publicado: (2021)

Rational Second-Generation Antiandrogen Use in Prostate Cancer
por: Orme, Jacob J, et al.
Publicado: (2022)

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
por: Merkens, Lina, et al.
Publicado: (2022)

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
por: Verma, Shiv, et al.
Publicado: (2020)

Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components
por: Soundararajan, Rama, et al.
Publicado: (2022)

Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants – In vivo evidence
por: Özten-Kandaş, Nur, et al.
Publicado: (2011)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade
por: Flaig, Thomas W., et al.
Publicado: (2017)

Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer
por: Nowakowska, Malgorzata K., et al.
Publicado: (2021)

Role of prostate cancer stem-like cells in the development of antiandrogen resistance
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
por: Congregado Ruiz, Belén, et al.
Publicado: (2023)

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures
por: Vasaikar, Suhas V., et al.
Publicado: (2020)

Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
por: Zhang, Zeda, et al.
Publicado: (2020)

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?
por: Yekedüz, Emre, et al.
Publicado: (2021)

Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer
por: Dong, Baijun, et al.
Publicado: (2020)

The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy
por: Seed, Robert I., et al.
Publicado: (2019)

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer
por: Brown, Landon C., et al.
Publicado: (2022)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance
por: Ottman, Richard, et al.
Publicado: (2014)

Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment
por: Ivachtchenko, Alexandre V., et al.
Publicado: (2014)

Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells
por: Brooke, Greg N., et al.
Publicado: (2015)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism
por: Gheorghe, Andrei Cristian Dan, et al.
Publicado: (2020)

Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives
por: Pinto, Francesco, et al.
Publicado: (2022)

De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc
por: Kwon, Oh-Joon, et al.
Publicado: (2020)

FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition
por: Pietilä, Mika, et al.
Publicado: (2016)

Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence
por: Aouad, Patrick, et al.
Publicado: (2022)

Single luminal epithelial progenitors can generate prostate organoids in culture
por: Chua, Chee Wai, et al.
Publicado: (2014)

Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention
por: Nouri, Mannan, et al.
Publicado: (2014)

Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
por: Paranjape, A N, et al.
Publicado: (2016)

Advantage of soybean isoflavone as antiandrogen on acne vulgaris
por: Riyanto, Puguh, et al.
Publicado: (2015)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade
por: Choi, Joon Il, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_k0bmtav5v3o2e88s4hp68iitjl